Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
While much has been written about the distinctions between biologics and small molecules in terms of their scientific, manufacturing and regulatory experiences, relatively little has been published comparing their clinical and commercial experiences. Employing a data base encompassing all 96 biol...
Main Authors: | Trusheim, Mark, Aitken, Murray L., Berndt, Ernst R. |
---|---|
Other Authors: | Sloan School of Management |
Format: | Article |
Language: | en_US |
Published: |
National Bureau of Economic Research
2011
|
Online Access: | http://hdl.handle.net/1721.1/62181 https://orcid.org/0000-0002-6388-0768 |
Similar Items
-
Investigating investment in biopharmaceutical R&D
by: Carter, Percy H., et al.
Published: (2017) -
Biophysical characterization of proteins in developing biopharmaceuticals /
by: Houde, Damian J., editor, et al.
Published: (2015) -
Innovation and commercialisation in the biopharmaceutical industry : creating and capturing value /
by: 516435 Rasmussen, Bruce
Published: (2010) -
Lyophilization of biopharmaceuticals /
by: Costantino, Henry R., et al.
Published: (2004) -
Integrating ESG Pillars for Business Model Innovation in the Biopharmaceutical Industry
by: Annesha Bhattacharya, et al.
Published: (2023-02-01)